NO20045002L - (1-4-piperidinyl) benzimidazolderivater som kan anvendes som histamin H3-antagonister - Google Patents

(1-4-piperidinyl) benzimidazolderivater som kan anvendes som histamin H3-antagonister

Info

Publication number
NO20045002L
NO20045002L NO20045002A NO20045002A NO20045002L NO 20045002 L NO20045002 L NO 20045002L NO 20045002 A NO20045002 A NO 20045002A NO 20045002 A NO20045002 A NO 20045002A NO 20045002 L NO20045002 L NO 20045002L
Authority
NO
Norway
Prior art keywords
formula
histamine
antagonists
compounds
piperidinyl
Prior art date
Application number
NO20045002A
Other languages
English (en)
Norwegian (no)
Inventor
Stuart B Rosenblum
Joseph A Kozlowski
Michael Y Berlin
Christopher W Boyce
Mwangi Wa Mutahi
Neng-Yang Shih
Wing C Tom
Kevin D Mccormick
Robert G Aslanian
Pietro Mangiaracina
Qingbei Zeng
Jianhua Cao
Daniel M Solomon
Cao Jianhua
Gg Venerraceesrange
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20045002L publication Critical patent/NO20045002L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20045002A 2002-04-18 2004-11-17 (1-4-piperidinyl) benzimidazolderivater som kan anvendes som histamin H3-antagonister NO20045002L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37373102P 2002-04-18 2002-04-18
PCT/US2003/011672 WO2003088967A1 (en) 2002-04-18 2003-04-16 (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists

Publications (1)

Publication Number Publication Date
NO20045002L true NO20045002L (no) 2005-01-18

Family

ID=29251069

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045002A NO20045002L (no) 2002-04-18 2004-11-17 (1-4-piperidinyl) benzimidazolderivater som kan anvendes som histamin H3-antagonister

Country Status (26)

Country Link
EP (1) EP1499316B1 (de)
JP (1) JP4384918B2 (de)
KR (1) KR100827470B1 (de)
CN (1) CN100522166C (de)
AR (1) AR040405A1 (de)
AT (1) ATE389406T1 (de)
AU (1) AU2003223627B2 (de)
BR (1) BR0309348A (de)
CA (1) CA2481940A1 (de)
CY (1) CY1110363T1 (de)
DE (1) DE60319813T2 (de)
DK (1) DK1499316T3 (de)
EC (1) ECSP045367A (de)
ES (1) ES2301791T3 (de)
IL (1) IL164584A (de)
MX (1) MXPA04010173A (de)
NO (1) NO20045002L (de)
NZ (1) NZ535763A (de)
PE (1) PE20040684A1 (de)
PL (1) PL373889A1 (de)
PT (1) PT1499316E (de)
RU (1) RU2323935C2 (de)
SI (1) SI1499316T1 (de)
TW (1) TW200306183A (de)
WO (1) WO2003088967A1 (de)
ZA (1) ZA200407984B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511970C (en) 2003-01-14 2012-06-26 Cytokinetics, Inc. Urea derivatives useful in the treatment of heart failure
PL1615909T3 (pl) 2003-04-23 2009-01-30 Glaxo Group Ltd Pochodne piperazyny i ich zastosowanie w leczeniu chorób neurologicznych i psychicznych
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
WO2006038738A1 (ja) * 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited 受容体機能調節剤
CN101107231A (zh) 2005-01-21 2008-01-16 先灵公司 用作组胺h3拮抗剂的咪唑和苯并咪唑衍生物
EP1896453B1 (de) * 2005-06-20 2009-12-02 Schering Corporation Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten
DE602006010870D1 (de) 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
JP4860700B2 (ja) * 2005-09-20 2012-01-25 シェーリング コーポレイション ヒスタミンH3アンタゴニストとして有用な、1−[[1−[(2−アミノ−6−メチル−4−ピリジニル)メチル]−4−フルオロ−4−ピペリジニル]カルボニル]−4−[2−(2−ピリジニル)−3H−イミダゾ[4,5−b]ピリジン−3−イル]ピペリジン
CN101273026A (zh) 2005-09-30 2008-09-24 霍夫曼-拉罗奇有限公司 作为mch受体拮抗剂的茚满衍生物
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
EP1959962A2 (de) 2005-12-16 2008-08-27 Cytokinetics, Inc. Bestimmte chemische stoffe, zusammensetzungen und verfahren
EP1962852B1 (de) 2005-12-19 2017-01-25 Cytokinetics, Inc. Verbindungen, zusammensetzungen und verfahren
US20070142369A1 (en) * 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンh3アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
AU2007204426A1 (en) * 2006-01-13 2007-07-19 F. Hoffmann-La Roche Ag Cyclohexyl piperazinyl methanone derivatives and their use as histamine H3 receptor modulators
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
RU2486187C2 (ru) * 2007-09-11 2013-06-27 Эбботт Лэборетриз N-ОКСИДЫ ОКТАГИДРО-ПИРРОЛО[3,4-b]ПИРРОЛА
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
DK2519522T3 (en) 2009-12-30 2014-12-08 Arqule Inc SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS
KR20190015600A (ko) 2011-06-24 2019-02-13 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
KR101127756B1 (ko) 2011-09-02 2012-03-23 한국과학기술원 Git1 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6046646B2 (ja) 2014-01-10 2016-12-21 信越化学工業株式会社 オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法
US10595550B2 (en) * 2014-01-22 2020-03-24 Vision Pharma, Llc Therapeutic composition including carbonated solution
WO2017035114A1 (en) * 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as cb-1 inverse agonists
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD290192A5 (de) * 1986-11-13 1991-05-23 Eisai Co. Ltd,Jp Pyridinderivat mit antiulzeroeser wirkung
ES2048109B1 (es) * 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
ATE174908T1 (de) * 1993-05-26 1999-01-15 Sumitomo Pharma Chinazolinonderivate
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
PT888336E (pt) * 1996-02-21 2002-12-31 Aventis Pharma Inc Novas n-metil-n-(4-(4-(1h-benzimidazol-2-il-amino)-piperidina-1-il)-2-(aril)-butil)-benzamidas substituidas uteis para o tratamento de doencas alergicas
AU730650B2 (en) * 1997-05-01 2001-03-08 Nissan Chemical Industries Ltd. Benzimidazole derivative
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
AR030946A1 (es) * 2000-09-20 2003-09-03 Schering Corp Derivados de imidazoles sustituidos un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos como agonistas o antagonistas duales de h1 y h3 de histamina
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
NZ535764A (en) * 2002-04-18 2007-10-26 Schering Corp 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists

Also Published As

Publication number Publication date
ES2301791T3 (es) 2008-07-01
PL373889A1 (en) 2005-09-19
PE20040684A1 (es) 2004-10-05
AU2003223627C1 (en) 2003-11-03
EP1499316B1 (de) 2008-03-19
JP4384918B2 (ja) 2009-12-16
MXPA04010173A (es) 2005-02-03
CY1110363T1 (el) 2012-05-23
ECSP045367A (es) 2004-11-26
AU2003223627A1 (en) 2003-11-03
ATE389406T1 (de) 2008-04-15
DE60319813T2 (de) 2009-04-23
NZ535763A (en) 2007-06-29
PT1499316E (pt) 2008-06-30
RU2004133764A (ru) 2005-07-20
SI1499316T1 (sl) 2008-08-31
IL164584A (en) 2010-12-30
JP2005529116A (ja) 2005-09-29
ZA200407984B (en) 2005-10-18
BR0309348A (pt) 2005-03-01
CN100522166C (zh) 2009-08-05
KR20040099445A (ko) 2004-11-26
AR040405A1 (es) 2005-04-06
DK1499316T3 (da) 2008-07-21
WO2003088967A1 (en) 2003-10-30
CA2481940A1 (en) 2003-10-30
RU2323935C2 (ru) 2008-05-10
IL164584A0 (en) 2005-12-18
KR100827470B1 (ko) 2008-05-06
HK1067981A1 (en) 2005-04-22
EP1499316A1 (de) 2005-01-26
TW200306183A (en) 2003-11-16
DE60319813D1 (de) 2008-04-30
AU2003223627B2 (en) 2006-10-12
CN1658874A (zh) 2005-08-24

Similar Documents

Publication Publication Date Title
NO20045002L (no) (1-4-piperidinyl) benzimidazolderivater som kan anvendes som histamin H3-antagonister
MY135686A (en) Indole derivatives useful as histamine h3 antagonists
CA2482551A1 (en) 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20050828L (no) lndol-3-svovelderivater
NO20055219L (no) Nye forbindelser
WO2002072570A3 (en) Non-imidazole compounds as histamine h3 antagonists
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20022857L (no) Nye P2X7-reseptoragonister for bruk i behandling av inflammatoriske, immun- eller kardiovaskul¶re sykdommer
NO20064577L (no) Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20051527D0 (no) 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
NO20063382L (no) Nye kinolinderivater
NO20071140L (no) Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
ATE346058T1 (de) Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon
BRPI0408727A (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar de uma condição ou estado de doença mediados pela atividade da quinase p38 ou mediados pelas citocinas produzidas pela atividade da quinase p38, e, uso de um composto
EP1201239A4 (de) Cyclische amine als ccr3 antagonisten
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20055977L (no) Nye benzimidazolderivater
NO20055256D0 (no) 4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers
BRPI0519398A2 (pt) compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina